References
- Berlie HD, Garwood CL. Diabetes medications related to an increased risk of falls and fall-related morbidity in the elderly. Ann Pharmacother 2010;44:712-7
- Tamez-Pérez HE, Proskauer-Peña SL, Hernŕndez-Coria MI, et al. AACE Comprehensive Diabetes Management Algorithm. Endocr Pract 2013;19:736-37
- Katsiki N, Athyros VG, Karagiannis A. Single-pill combinations: a therapeutic option or necessity for vascular risk treatment? J Drug Assess 2013;2:67-71
- Schernthaner G. Fixed-dose combination therapies in the management of hyperglycaemia in Type 2 diabetes: an opportunity to improve adherence and patient care. Diabet Med 2010;27:739-43
- Williams S, Buysman EK, Hulbert EM, et al. Hemoglobin A1c outcomes and health care resource use in type 2 diabetes mellitus patients treated with combination oral antidiabetic drugs through step therapy and loose-dose and fixed-dose combinations. Manag Care 2012;21:40-8
- Hutchins V, Zhang B, Fleurence RL, et al. A systematic review of adherence, treatment satisfaction and costs, in fixed-dose combination regimens in type 2 diabetes. Curr Med Res Opin 2011;27:1157-68
- Scheen AJ. Saxagliptin plus metformin combination therapy. Exp Rev Endocrinol Metab 2012;7:151-64
- Hiroi S, Sugiura K, Matsuno K, et al. A multicenter, phase III evaluation of the efficacy and safety of a new fixed-dose pioglitazone/glimepiride combination tablet in Japanese patients with type 2 diabetes. Diabetes Technol Ther 2013;15:158-65
- Engel SS, Seck TL, Golm GT, et al. Assessment of AACE/ACE recommendations for initial dual antihyperglycemic therapy using the fixed-dose combination of sitagliptin and metformin versus metformin. Endocr Pract 2013;19:751-7
- Steinberg H, Anderson MS, Musliner T, et al. Management of dyslipidemia and hyperglycemia with a fixed-dose combination of sitagliptin and simvastatin. Vasc Health Risk Manag 2013;9:273-82
- Melikian C, White TJ, Vanderplas A, et al. Adherence to oral antidiabetic therapy in a managed care organization: a comparison of monotherapy, combination therapy, and fixed-dose combination therapy. Clin Ther 2002;24:460-7
- Cheong C, Barner JC, Lawson KA, et al. Patient adherence and reimbursement amount for antidiabetic fixed-dose combination products compared with dual therapy among Texas Medicaid recipients. Clin Ther 2008;30:1893-907
- Bell DS. Combine and conquer: advantages and disadvantages of fixed-dose combination therapy. Diabetes Obes Metab 2013;15.4:291-300
- Benford M, Milligan G, Pike J, et al. Fixed-dose combination antidiabetic therapy: real-world factors associated with prescribing choices and relationship with patient satisfaction and compliance. Adv Ther 2012;29:26-40
- Curkendall SM, Zhang B, Lenhart G, et al. Rate of hypoglycemia in patients with type 2 diabetes receiving metformin plus saxagliptin versus metformin plus sulfonylurea: a retrospective observational cohort study using administrative claims data. Exp Rev Endocrinol Metab 2014;9:183-91
- US Bureau of Labor Statistics. Consumer Price Index. 2014. Available from http://www.bls.gov/cpi/. [Last accessed December 2014].
- Brook RA, Kleinman NL, Wingenbach D, et al. Medication possession ratio and health benefit cost comparisons in type 2 diabetes patients using fixed-and loose-dose thiazolidinedione combination products. Diabetes 2008;57(1 Suppl):A346
- Colombo GL, Rossi E, De Rosa M, et al. Antidiabetic therapy in real practice: indicators for adherence and treatment cost. Patient Prefer Adherence 2012;6:653-61
- Derosa G, Maffioli P. Patient considerations and clinical utility of a fixed dose combination of saxagliptin/metformin in the treatment of type 2 diabetes. Diabetes Metab Syndr Obes 2011;4:263-71
- García-Pérez L-E, Álvarez M, Dilla T, et al. Adherence to therapies in patients with type 2 diabetes. Diabetes Ther 2013;4:175-94
- Doggrell SA, Warot S. The association between the measurement of adherence to anti-diabetes medicine and the HbA1c. Int J Clin Pharm 2014;36:488-97